Intelligent Bio Solutions Inc. (NASDAQ: INBS) showcased their “Innovative Drug Screening Technology ” at the International Mining and Resources Conference (IMARC) in Sydney, Australia this week. The company’s innovative sweat-based drug screening solution garnered significant interest at the conference from attendees across a variety of roles and industries.
IMARC has become a leading event in the global mining industry, with a diverse range of participants, including government representatives from various countries and delegates from influential mining companies, including BHP, Anglo American, and Agnico Eagle Mines. More than 40% of attendees are C-suite executives, highlighting the importance of IMARC within the mining sector.
Intelligent Bio Solutions’ drug screening solution addresses a critical need in the mining industry, particularly in the areas of exploration , production, safety consulting, and medical services labor hire. The 16-hour window of detection and the non-invasive collection method are key factors that have piqued the interest of professionals in attendance.
The positive response and interest from the industry, as mentioned by Peter Passaris, the Vice President of Sales and Operations at Intelligent Bio Solutions, reflect the potential for the company’s solution to make a significant impact on the safety culture of mining organizations. It’s clear that the company has achieved its goal of increasing brand and product awareness at the conference.
Furthermore, Intelligent Bio Solutions appears well-positioned to capitalize on the momentum it has generated and explore further opportunities to promote their drug screening technology throughout the mining industry among other industries in this type of conference environment, which could potentially lead to valuable partnerships and collaborations within the mining industry sector among other industry sectors.
Cellectis (NASDAQ: CLLS) is a clinical-stage biotech company involved in deploying its gene editing platform for the development of life-saving gene and cell therapies.
On November 1, Cellectis announced that it had entered into a joint research collaboration agreement, an investment agreement pertaining to an equity investment of $80 million, and a MoU (memorandum of understanding) for an additional $140 million equity investment with AstraZeneca. Through the collaboration agreement, the company would work on speeding up the development of its next generation of therapeutics in areas with significant unmet needs. The areas include oncology, rare diseases, and immunology.
As per the terms of the agreement, AstraZeneca would use the proprietary gene editing technologies and manufacturing capacities of Cellectis to design unique gene and cell therapy products. It was also revealed in the news release that, as per the agreement, 25 genetic targets had been reserved for AstraZeneca exclusively. Out of those, 10 candidates could be used for further development.
Precision BioSciences Inc. (NASDAQ: DTIL), the advanced gene editing company, is involved in deploying its proprietary ARCUS platform for the development of in vivo gene editing therapies for highly complex gene edits. Precision BioSciences Inc. announced on October 26 that it would have two posters highlighting the capacities of the ARCUS platform at the ESGCT 30th Annual Congress.
The posters would advertise the distinct capacity of the platform to make durable, efficient, and targeted insertion edits in NHPs (non-human primates). Additionally, the company noted that the posters would also show preclinical data, showing the potential of the platform to hit a large excision of a common mutated region of the dystrophin gene. That could help in coming up with treatments for Duchenne muscular dystrophy. In the preclinical work that was presented at the time, the platform displayed high-energy gene insertion in vitro and in vivo.
Ocular Therapeutix Inc. (NASDAQ:OCUL) The biopharmaceutical company is involved in the development, formulation, and commercialization of innovative therapies for treating eye-related diseases and conditions. On November 1 Ocular Therapeutix Inc announced that the United States Food and Drug Administration had provided a written agreement pertaining to its testing protocol for the Phase 3 clinical trial of AXPAXLI.
The written agreement had been provided to the company under the provisions of a Special Protocol Assessment (SPA). The company revealed that the product is meant for treating wet macular degeneration brought about by age. Ocular Therapeutix refers to the trial as the SOL trial, which had been initiated in September and was expected to enroll 300 subjects who could be evaluated for the condition. The trial had been designed by a multi-centre parallel group trial run and would mainly be held at sites in the United States.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.